Cargando…
An update review of emerging small-molecule therapeutic options for COVID-19
The SARS-CoV-2 outbreak and pandemic that began near the end of 2019 has posed a challenge to global health. At present, many candidate small-molecule therapeutics have been developed that can inhibit both the infection and replication of SARS-CoV-2 and even potentially relieve cytokine storms and o...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Masson SAS.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857046/ https://www.ncbi.nlm.nih.gov/pubmed/33556871 http://dx.doi.org/10.1016/j.biopha.2021.111313 |
_version_ | 1783646367992774656 |
---|---|
author | Tian, Dengke Liu, Yuzhi Liang, Chengyuan Xin, Liang Xie, Xiaolin Zhang, Dezhu Wan, Minge Li, Han Fu, Xueqi Liu, Hong Cao, Wenqiang |
author_facet | Tian, Dengke Liu, Yuzhi Liang, Chengyuan Xin, Liang Xie, Xiaolin Zhang, Dezhu Wan, Minge Li, Han Fu, Xueqi Liu, Hong Cao, Wenqiang |
author_sort | Tian, Dengke |
collection | PubMed |
description | The SARS-CoV-2 outbreak and pandemic that began near the end of 2019 has posed a challenge to global health. At present, many candidate small-molecule therapeutics have been developed that can inhibit both the infection and replication of SARS-CoV-2 and even potentially relieve cytokine storms and other related complications. Meanwhile, host-targeted drugs that inhibit cellular transmembrane serine protease (TMPRSS2) can prevent SARS-CoV-2 from entering cells, and its combination with chloroquine and dihydroorotate dehydrogenase (DHODH) inhibitors can limit the spread of SARS-CoV-2 and reduce the morbidity and mortality of patients with COVID-19. The present article provides an overview of these small-molecule therapeutics based on insights from medicinal chemistry research and focuses on RNA-dependent RNA polymerase (RdRp) inhibitors, such as the nucleoside analogues remdesivir, favipiravir and ribavirin. This review also covers inhibitors of 3C-like protease (3CL(pro)), papain-like protease (PL(pro)) and other potentially innovative active ingredient molecules, describing their potential targets, activities, clinical status and side effects. |
format | Online Article Text |
id | pubmed-7857046 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Author(s). Published by Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78570462021-02-04 An update review of emerging small-molecule therapeutic options for COVID-19 Tian, Dengke Liu, Yuzhi Liang, Chengyuan Xin, Liang Xie, Xiaolin Zhang, Dezhu Wan, Minge Li, Han Fu, Xueqi Liu, Hong Cao, Wenqiang Biomed Pharmacother Review The SARS-CoV-2 outbreak and pandemic that began near the end of 2019 has posed a challenge to global health. At present, many candidate small-molecule therapeutics have been developed that can inhibit both the infection and replication of SARS-CoV-2 and even potentially relieve cytokine storms and other related complications. Meanwhile, host-targeted drugs that inhibit cellular transmembrane serine protease (TMPRSS2) can prevent SARS-CoV-2 from entering cells, and its combination with chloroquine and dihydroorotate dehydrogenase (DHODH) inhibitors can limit the spread of SARS-CoV-2 and reduce the morbidity and mortality of patients with COVID-19. The present article provides an overview of these small-molecule therapeutics based on insights from medicinal chemistry research and focuses on RNA-dependent RNA polymerase (RdRp) inhibitors, such as the nucleoside analogues remdesivir, favipiravir and ribavirin. This review also covers inhibitors of 3C-like protease (3CL(pro)), papain-like protease (PL(pro)) and other potentially innovative active ingredient molecules, describing their potential targets, activities, clinical status and side effects. The Author(s). Published by Elsevier Masson SAS. 2021-05 2021-02-03 /pmc/articles/PMC7857046/ /pubmed/33556871 http://dx.doi.org/10.1016/j.biopha.2021.111313 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Tian, Dengke Liu, Yuzhi Liang, Chengyuan Xin, Liang Xie, Xiaolin Zhang, Dezhu Wan, Minge Li, Han Fu, Xueqi Liu, Hong Cao, Wenqiang An update review of emerging small-molecule therapeutic options for COVID-19 |
title | An update review of emerging small-molecule therapeutic options for COVID-19 |
title_full | An update review of emerging small-molecule therapeutic options for COVID-19 |
title_fullStr | An update review of emerging small-molecule therapeutic options for COVID-19 |
title_full_unstemmed | An update review of emerging small-molecule therapeutic options for COVID-19 |
title_short | An update review of emerging small-molecule therapeutic options for COVID-19 |
title_sort | update review of emerging small-molecule therapeutic options for covid-19 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857046/ https://www.ncbi.nlm.nih.gov/pubmed/33556871 http://dx.doi.org/10.1016/j.biopha.2021.111313 |
work_keys_str_mv | AT tiandengke anupdatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT liuyuzhi anupdatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT liangchengyuan anupdatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT xinliang anupdatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT xiexiaolin anupdatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT zhangdezhu anupdatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT wanminge anupdatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT lihan anupdatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT fuxueqi anupdatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT liuhong anupdatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT caowenqiang anupdatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT tiandengke updatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT liuyuzhi updatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT liangchengyuan updatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT xinliang updatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT xiexiaolin updatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT zhangdezhu updatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT wanminge updatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT lihan updatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT fuxueqi updatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT liuhong updatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 AT caowenqiang updatereviewofemergingsmallmoleculetherapeuticoptionsforcovid19 |